Skip to main content

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Sarepta Therapeutics

Sarepta Therapeutics

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

You are here

  • Home
  • News Features

News Features

ami kabadi
01/13/2021
How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
together we soar
12/18/2020
Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
GT-FAQ
10/14/2020
Welcome to GT‐FAQ!
style="margin: 0 0 2em 2em;"
09/29/2020
Expanding Access to Newborn Screening for Those with Rare Diseases
Alex headshot full res
09/14/2020
Room to Grow – From Sarepta Intern to Making Impact on the Pipeline
julianna thumbnail
06/12/2020
Patiently Waiting
zhang teaser
03/17/2020
A Playbook for Sustainable Gene Therapy Manufacturing
Jungels
03/17/2020
From Art to Science: How One Sarepta Scientist Brings the Arts into the Lab
Duchenne FAP
03/02/2020
Advocacy Community Unites to Support Families
How Sarepta Infused feature image
02/25/2020
How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients

Pagination

  • Page 1
  • Next page ››

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2021 Sarepta Therapeutics All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy